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Description: Pain in patients with chronic pancreatitis (CP) remains the primary clinical complaint and
source of poor quality of life. However, clear guidance on evaluation and treatment is lacking.
Methods: Pancreatic Pain working groups reviewed information on pain mechanisms, clinical pain
assessment and pain treatment in CP. Levels of evidence were assigned using the Oxford system, and
consensus was based on GRADE. A consensus meeting was held during PancreasFest 2012 with sub-
stantial post-meeting discussion, debate, and manuscript reﬁnement.
Results: Twelve discussion questions and proposed guidance statements were presented. Conference
participates concluded: Disease Mechanism: Pain etiology is multifactorial, but data are lacking to
effectively link symptoms with pathologic feature and molecular subtypes. Assessment of Pain: Pain
should be assessed at each clinical visit, but evidence to support an optimal approach to assessing pain
character, frequency and severity is lacking. Management: There was general agreement on the roles for
endoscopic and surgical therapies, but less agreement on optimal patient selection for medical, psy-
chological, endoscopic, surgical and other therapies.
Conclusions: Progress is occurring in pain biology and treatment options, but pain in patients with CP
remains a major problem that is inadequately understood, measured and managed. The growing body of
information needs to be translated into more effective clinical care.
Copyright © 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).* Corresponding author. GI Administration, University of Pittsburgh/UPMC, Room 401.4, 3708 Fifth Ave, Pittsburgh, PA 15213, USA. Tel.: þ1 412 578 9515; fax: þ1 412 578b).
by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. This is an open access article under the CC BY-NC-ND license
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Chronic pancreatitis (CP) is a chronic inﬂammatory disorder of
the pancreas that is complicated by severe, constant and
disabling pain in nearly half of all patients [1] and leads to some
of the worst quality of life (QOL) scores for any chronic disease
[1e3]. Chronic pancreatitis was considered a disease of alco-
holism until the discovery that smoking, complex genotypes, and
other factors accounted for the underlying etiology in over half of
all cases of this disease [4e6]. Studies of patients with CP and
pain indicate that there are multiple pain patterns, characteristics
and severity levels, and that morphology on abdominal imaging
may not correlate with pain features [7]. The strongest predictor
of poor quality of life and disability among complications of CP is
constant pain [1]. Recent studies have addressed the quality of
life [2,8], and comparative effectiveness of treatment for neuro-
pathic pain [9,10] and outcomes of both endoscopic and surgical
treatments [11,12]. Finally, there is growing use of total pancre-
atectomy with islet autotransplantation (TPIAT) for control of
pain [13e15].
Several recent guidelines for the general management of pain in
CP have been published [15e18]. In addition, speciﬁc guidelines for
the endoscopic treatment of pain were published by consensus of a
working group supported by the European Society of Gastroin-
testinal Endoscopy (ESGE) [19]. These documents carefully
addressed several clinical questions from existing literature and by
discussion. The evolving literature on pancreatitis-associated pain,
advances in the neuroscience of pain [3], various methods for
assessing pain and new treatment options, including total
pancreatectomy with TPIAT justify a comprehensive review, iden-
tiﬁcation of knowledge gaps and recommendations for future
research.Guideline focus
The clinical recommendations guide the evaluation and man-
agement of pain in adult patients with recurrent acute pancreatitis
(AP) and chronic pancreatitis. Inadequate data on pediatric groups
precluded inclusion of this important population in the current
review.
The problem of pain in CP is well recognized, and represents a
major area of emphasis by the clinicaletranslational working
groups meeting at PancreasFest. In addition to regular working
group meetings, a comprehensive, multidisciplinary review of the
problem of pain in CP was undertaken over a three-year period at
the annual PancreasFest meeting, as previously described [15,20].
The PancreasFest working groups were organized by academic
physicians and scientists associated with the North American
Pancreatitis Study Group (see NAPS2 [4]) and the Center for Pain
Research, University of Pittsburgh (www.paincenter.pitt.edu) who
had an interest in pancreatic pain. The Pain Working Group was
further developed by inviting content experts to participate in the
process. Ad Hoc sub-groups were organized to develop and frame
discussion questions and guiding statements in three areas: 1)
mechanisms of pain in CP; 2) the assessment of pain; and 3) the
treatment of pain, including TPIAT.Evidence review and grading
Levels of evidence were ranked based on the Oxford Center for
Evidence-Based Medicine's system [21]. Consensus was assessed
using the Grading of Recommendations Assessment, Development
and Evaluation (GRADE) grid for the clinical guideline statements
[22].Evidence and discussion
The working group included physicians and scientists who
regularly attend PancreasFest, expressed a primary interest in
pancreatic pain, and met as a group during break-out sessions.
Primary areas of interest and need were identiﬁed by discussion
and presentations in year one. The ad hoc group was encouraged to
invite the participation of other experts, and to organize and pri-
oritize the state-of-the-art and state-of-the-science, and present
their priorities to the larger group at the subsequent PancreasFest
meeting. Dr. Anderson organized the PancreasFest working groups,
and the process of developing discussion questions was initiated,
with reﬁnement and focus during the third year.
The ﬁnal discussion questions presented to attendees of Pan-
creasFest 2012 were followed by one or more guidance statements
intended to provide a concise summary and, if indicated, a clinical
recommendation or guidance. The initial recommendations were
presented to the audience and projected onto a screen on a
statement-by-statement basis. The audience, which was approxi-
mately 90% MD or MD-PhD, 4% PhD and 6% others, such as study
nurses (Appendix), responded to the draft guidance statements for
speciﬁc clinical questions and then indicated their level of agree-
ment based on a 5-point scale (strong positive, weak positive, un-
certain or equivocal, weak negative, strong negative) using digital
voting devices. Conference attendees discussed the initial questions
and guidance statements of theworking group. The responses were
tabulated and projected for the entire conference to discuss and
revise in real-time. The conference participants then voted again on
the level of agreement with each statement that, after discussion,
required more information or clariﬁcation. The participants sent
additional comments to the study members by email to be
considered in the ﬁnal discussion.
The working groups revised and extended the evidence and
discussion sections for each question over a two-year period with
updated references. The focus was to improve accuracy and speci-
ﬁcity in each statement, improve clarity, and re-review controver-
sial areas. In addition, common ground and agreement of experts
from different disciplines with different approaches was sought
throughout the manuscript writing, review and rewriting process.
All working group members reviewed each major version of the
document, and all participants who participated in the discussion
and reviewed and approved the ﬁnal document are included as co-
authors.
Results
Part 1. Mechanisms of pain in chronic pancreatitis
Three broad discussion questions were developed. Question 2
was subdivided to address speciﬁc issues.
Discussion Question 1: What causes pain in chronic
pancreatitis?
Guidance Statement 1: Pain in CP may arise from mechanical
(intraductal pressure/obstruction), inﬂammatory, malabsorptive or
neurogenic/neuropathic changes in the pancreas and/or sur-
rounding organs.
Evidence Level: 2b
Grade of recommendation: B
Level of Agreement: A 89%; B 9%; C 0%; D 0%; E 2%.
Evidence and Discussion: Pancreatic duct obstruction, stric-
tures, and/or peri-pancreatic ﬁbrosis may cause ductal hyperten-
sion or ischemia from a stricture or a compartment syndrome
leading to pain [23e26]. However, whenmeasured, pancreatic duct
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are not predictive of pain relief in patients undergoing surgical or
endoscopic stone removal or stenting [27]. The most convincing
data that pancreatic duct abnormalities cause pain are studies
demonstrating pain relief in patients undergoing decompressive
surgery (e.g. pancreaticojejunostomy) or endoscopic sphincter-
otomy, pancreatic stone extraction, and/or pancreatic duct stenting
[28,29]. Among study patients, 34% had sustained pain relief 5 years
after surgery, whereas only 15% of patients were pain-free
following endotherapy [29]. Neither technique, using the re-
ported patient selection criteria, provides optimal long-term pain
relief. Sham-controlled studies of endoscopic or surgical decom-
pressive therapies are lacking.
Alterations in nociception have been associated with both
experimental and human CP [3]. Sensory nerve excitability is
increased in animals with CP and is accompanied by upregulation
of calcitonin gene-related peptide (CGRP), substance P and brain-
derived neurotrophic factor (BDNF) [30e32], which also signal
pain. Pharmacological blockade of these transmitters improves
pain. Additionally, release of neuropeptides such as CGRP and
substance P, produce classic features of inﬂammation, including
edema, necrosis and neutrophil inﬁltration [33]. Nerve growth
factor (NGF), which plays a key role in regulating neuronal activa-
tion and receptor expression (e.g., transient receptor potential
cation channel subfamily V member 1 [TRPV1]), is ectopically
expressed in acinar and ductal tissues in CP [30,34]. Anti-NGF
therapy suppresses substance P and CGRP expression and reduces
pancreatic pain [32].
Inﬂammation is a major source of pancreatic pain. Immune cells
inﬁltrating the pancreas with release of cytokines and chemokines,
such as IL-8 and fractalkine, have also been linked to pancreatic
pain [35,36]. Pain in CP has been associated with increased
numbers of mast cells in the pancreas [37]. Mast cells produce
tryptase, which can activate protease-activated receptor 2 (PAR2)
on sensory ﬁbers of the pancreas [37] and increase pain signaling.
PAR2 expression is elevated in human CP specimens [38]. Tissue
resected from patients with severe pancreatitis pain may exhibit
leukocytes inﬁltration of nerves, nerve hypertrophy and areas of
neuritis suggesting both inﬂammatory and neuropathic changes
underlie pain associated with CP [35,39].
Abdominal pain related to pancreatic disease may originate
from outside the pancreas. For example, in a 6-month open label
study, patients with proven pancreatic insufﬁciency taking pan-
crelipase at an average dose of 187K ± 75K lipase units/day, had
decreased pain severity, with the percent reporting no pain
increasing from 37.3% to 66.0% [40]. Among all patients, 44% had an
improvement in pain score while 10.6% reported worse pain [40]. A
reduction in ﬂatulence was also reported, raising the possibility
that the pain was linked with maldigestion. An older study sug-
gested that PERT reduces pancreatic pain directly in the context of
minimal change diseases, but replication studies are needed to
conﬁrm or refute these data [41].
Discussion Question 2.A: Are there pathologic features in the
pancreas or the peripheral nervous system of patients with chronic
pancreatitis that are associated with continuous, neuropathic-type
pain?
Guidance Statement: Some patients with CP and constant
neuropathic-type pain have changes in peripheral nerve ﬁber
anatomy and physiology. In some patients pain may not be asso-
ciated with changes in the peripheral nervous system.
Evidence Level: 5
Grade of recommendation: D
Level of Agreement: A 28%; B 26%; C 33%; D 5%; E 8%Evidence and Discussion: Pancreatic nerve hypertrophy and
intra/perineural inﬂammation have been described in human CP
and correlate with pancreatic pain severity [39]. The increased size
and excitability of pancreatic nerves appears to be due to the highly
neurotrophic environment produced by the inﬂamed pancreas.
There is elevation in growth factors and cytokines that promote
growth and/or sensitization of sympathetic and parasympathetic
efferents and sensory ﬁbers [3,30,39]. This environment also in-
creases neuronal expression of genes that cause sensitization
including TRPV1, TRPA1, TRPV4 and PAR2 [34,42e44].
In experimental models the application of antagonists for TRPV1
and TRPA1, channels required for inﬂammatory hyperalgesia, block
pain and prevent recurrent acute pancreatitis (RAP) from devel-
oping the hallmarks of CP, including ﬁbrosis and sustained
inﬂammation [45].
Pain associated with CP may result from negative synergistic
interactions between the pancreatic parenchyma, immune cells
and the PNS. Activated sympathetic ﬁbers can release molecules
(e.g. ATP) that sensitize sensory ﬁbers, as well as molecules (e.g.
epinephrine) that can activate immune cells. Release of NGF by
immune and acinar cells sensitizes sensory ﬁbers and induces
sprouting [37]. Sensitized primary afferents release CGRP and
glutamate, contributing to “neurogenic” inﬂammation.
Discussion Question 2.B: Are there speciﬁc pathologic features
in the pancreas or the central nervous system of patients with
chronic pancreatitis that are associated with pain?
Guidance Statement: Some patients with CP and pain have
changes in the central nervous system. These changes may indicate
alterations in central pain processing.
Evidence Level: 3b
Grade of recommendation: C
Level of Agreement: A 57%; B 29%; C 5%; D 0%; E 9%
Evidence and Discussion: Some patients with CP have evi-
dence of alterations in central pain processing. Patients may have
hypersensitivity in unaffected organs and an increased incidence
in referred pain. For example, CP patients are more sensitive to
painful abdominal and rectal stimuli [36]. This increased sensi-
tivity may reﬂect changes in central neuronal pathways of the
spinal cord and brain [46,47]. Brain MRI studies show alteration in
brain thickness and microstructure in cingulate and prefrontal
cortices correlating to CP patients' clinical pain scores [48,49],
reminiscent of changes seen in patients that suffer from other
chronic pain states (e.g. lower back pain) [50]. Pain from CP may
also lead to changes in cortical projections of the nociceptive
system [51].
In animal models, changes in the CNS have been reported at the
spinal cord level where non-neuronal cells, including microglia and
astrocytes, are activated [46,47]. These cells play a pivotal role in
central sensitization in a number of models of persistent neuro-
pathic pain.
Discussion Question 3: Are there genetic, environmental,
emotional or other factors that contribute to the variability of pain
in patients with chronic pancreatitis?
Guidance Statement: Genetic, environmental, including early
childhood events [52] and emotional factors [53] have been shown
to contribute to the variability of pain in a variety of disease sys-
tems. Currently there are insufﬁcient data in humans with CP to
deﬁne the mechanisms or relative contributions of these factors.
Evidence Level: 5
Grade of recommendation: D
Level of Agreement: A 82%; B 16%; C 2%; D 0% E 0%
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mechanisms that are related to genetic background [50]. Studies of
CP-related pain show no association of pain with genetic markers
linked to postsurgical chronic pain [35,39,42]. However, animal
studies as well as human twin and family studies reveal that up to
50% of various chronic pain syndromes can be attributed to heri-
table factors [35,55,56].
Some gene products may predispose an individual to more
intense or persistent pain or provide protection from such a pain
[55]. Having “pain risk alleles” may increase vulnerability to pain
(including CP-related pain), through individual and combined ef-
fects and interaction with environmental factors [55].
Although the genetic studies of pancreatic pain are still in their
infancy compared to studies on somatic pain or migraine, several
published reports have shown that certain genetic mechanisms of
pain development and/or persistence may be shared between so-
matic and visceral pain disorders; these include adrenergic and
serotoninergic pathways. For example, the serotonin-transporter-
linked polymorphic region (5HTTLPR) correlated with pain
severity in patients with irritable bowel syndrome [57,58], and
variation in beta-2 adrenergic receptor predicted pain-related
quality of life in patients with functional gastrointestinal di-
agnoses [58].
One reason for slow progress in understanding the genetic as-
pects of pancreatic pain is lack of comprehensive visceral pain
phenotypic assessment in CP patients. Within-case design and as-
sociation analysis of genetic polymorphisms with speciﬁc pain
phenotypes (such as constant vs. intermittent pain, pain severity/
intensity, etc) may be more sensitive for CP-related pain genetics
studies and reveal genetic factors that explain inter-individual
variability in perception of this pain. Genome-wide association
studies in large cohorts of CP patients with pain phenotypes are
anticipated to further advance the ﬁeld [62].
Part 2: assessment of pain and quality of life (QOL) in CP
Four discussion questions were developed.
Discussion Question 4: What is the minimum assessment of
pain that should be performed in patients with chronic pancreatitis
at baseline and at follow-up?
Guidance Statement: Pain should be evaluated at each visit to
assess character, frequency and intensity. When possible, validated
instruments should be used.
Evidence Level: 2b
Grade of recommendation: B
Level of Agreement: A 80%; B 17%; C 2%; D 0%; E 0%
Evidence and Discussion: The description of pain in patients
with CP should include its character, frequency and intensity.
Frequency may be one of the most under-appreciated parameters
in this ﬁeld. In a prospective cohort study, 186 patients had
constant pain patterns compared to 228 with intermittent pain
[1]. Regardless of the intensity of the pain, those with constant
pain patterns had higher rates of disability (OR 3.2 (95% CI
2.0e5.1)), hospitalizations (X2 ¼ 8.8, p ¼ 0.00001), pain medi-
cations (OR 4.4 (95% CI 2.8e6.8)), and lower QOL evaluations
(Mental Component Score; MCS 39.9 vs. 47.6, p < 0.001) (Physical
Component Score; PCS 33.3 vs. 42.2, p < 0.001) than those with
intermittent pain [1].
A number of instruments are currently available to evaluate pain
severity. The visual analog scale (VAS) is presented as a 10 cm line
anchored by verbal descriptors (no pain-worst pain) [70]. Although
it is easy to use, it does not measure pain character, frequency,
pattern or pain interference. The McGill questionnaire is a 15-itemscale (11 sensory, 4 affective) whose score is translated into a
sensory score, an affective score and a total score. In addition to the
15 item scale, it also includes a Present Pain Intensity (PPI) scale and
a VAS. The NIH Patient-Reported Outcome Measurement Infor-
mation System (PROMIS) instruments arewell validated and can be
measured reliably across different conditions [72].
Discussion Question 5: How should the impact of pain be
evaluated in patients with chronic pancreatitis?
Guidance Statement: Validated instruments should be used to
evaluate quality of life (QOL). This may include evaluation of
physical, social, and emotional functions.
Evidence Level: 2b
Grade of recommendation: C
Level of Agreement: A 56%; B 28%; C 9%; D 0%; E 7%
Evidence and Discussion: Chronic pancreatitis strongly im-
pacts a number of functions each of which can reduce a patient's
QOL. In a cohort study of 265 CP patients, physical function was
impaired in 25% of patients, emotional function in 15%, and the
perception of diminished overall health functionwas present in 19%
[73]. In the NAPS2 study 443 well-phenotyped CP subjects and 611
control subjects were assessed for QOL using the Short Form 12
(SF12) questionnaire [4]. The QOL in CP subjects was similar or
worse than the QOL of many other chronic conditions [2]. In
another recent study at 4 US pancreatic disease centers, 74% of 111
patients reported that work lives were altered by their disease, 60%
reported an effect on social lives and 46% reported an effect on
spouse/signiﬁcant other relationship [74]. This study also reported
that 80% of CP patients reported that they had not been treated
with respect and dignity on at least one visit to the ER being labeled
alcoholic or a drug seeker suggesting that self-esteem maybe
another domain with an impact on CP patients [74]. In a recent
smaller study, in addition to pain intensity, BMI and disease dura-
tion signiﬁcantly impacted quality of life [8]. Thus, multiple factors
associated with CP affect QOL.
Until recently, only generic instruments for the evaluation of
QOL have been available to evaluate these patients [75]. These
include Short-Form 36 (SF-36) and European Organization of
Research for the Treatment of Cancer (EORTC) questionnaires. Both
instruments have undergone extensive psychometric evaluation
[73,76]. The SF-12 has been thoroughly studied in CP [2,77,78]. In an
evaluation of 163 consecutive patients with CP, the SF-12 appeared
to outperform the EORTC in clinical practice [77]. The generic in-
struments appear to be robust in evaluating CP QOL and the SF12
has been followed sequentially over time in CP [79].
Recently, a new disease-speciﬁc instrument was developed for
the evaluation of quality of life in this group of patients:
Pancreatitis Quality of Life Instrument (PanQOLI) [80]. This is an
18 item questionnaire designed to be the ﬁrst disease-speciﬁc
instrument to evaluate QOL in CP [80]. It includes unique fea-
tures not found in generic instruments (economic factors, stigma)
and consists of 4 domains: physical function (5 items), social
function (5 items), emotional function (4 items) and self-esteem
(4-items) [81]. The presence of a self-esteem component is
unique to this disease-speciﬁc instrument and is believed by the
study group to make it more sensitive for the evaluation of this
group of patients.
Given that pain signiﬁcantly affects QOL, the use of these in-
struments provides an important measure of pain impact. At least
one of the QOL measures should therefore be used in measuring
disease progression, impact and treatment success in conjunction
with pain measures.
Discussion Question 6: In patients with chronic pancreatitis,
should psychosocial assessment be done?
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logical co-morbidities (e.g. anxiety, depression, opiate abuse) and
functional pain using validated instruments.
Evidence Level: 5
Grade of recommendation: D
Level of Agreement: A 48%; B38%; C 8%; D 2%; E4%
Evidence and Discussion: Pain behavior is a well-studied
phenomenon and is described in patients suffering from chronic
pain [82]. This behavior can be adaptive and helpful or maladaptive
and interfere with coping mechanisms. Examples of maladaptive
behaviors include the development of drug abuse/addiction
behavior, the development of distress and anxiety disorders that
interfere with coping mechanisms, and the development of clinical
depression that impairs the ability to deal with pain [83]. In a
structured, evidence-based review of the literature, 3.27% of
chronic pain patients (n ¼ 2507) were found to develop abuse/
addiction behavior and 11.5% of patients (n ¼ 2466) developed
aberrant drug-related behaviors [84].
There is no single instrument that is currently available to assess
these various psychosocial behaviors [66]. It is necessary to choose
an instrument that is considered to best evaluate the suspected
abnormal behaviors [85,86]. Given the complexity of the assessment
process, the working group members believe that referral to a pain
specialist with skills in behavioral psychology is reasonable, partic-
ularly if aberrant pain behavior is suspected and response to therapy
has been suboptimal. In addition to administering these assessment
instruments to determine the potential presence of aberrant
behavior, it is helpful for psychologists to offer interventions in this
difﬁcult subset of patients, including the Interdisciplinary Pain
Rehabilitation Program (IPRP) [96]. Such an approach appears to be
cost-effective in this sub-group of patients, as studies demonstrate
that approximately 49% of patients can return to work with signiﬁ-
cantly reduced levels of depression, pain-related catastrophizing and
pain intensity, but no change in anxiety levels [97]. Furthermore,
studies inpatientswith chronic back pain have demonstrated that an
IPRP is 10.6 times more cost-effective than the use of Spinal Cord
Stimulators (SCS), 12 times more than standard medical care and 26
times more than surgery [98,99].
Therefore, it is crucial to evaluate the psychosocial impact of
chronic pancreatitis in addition to the pain and quality of life
evaluation previously discussed. The suggested instruments for this
evaluation would include the Pain-Anxiety Scale (PASS) [87], the
Pain Catastrophizing Scale (PCS) [88,89], the Drug Abuse Screening
Test (DAST) [90], the brief Michigan Alcohol Screening Test
(bMAST) [86], and/or the Current Opioid Misuse Measure (COMM).
If patients are found to have psychosocial dysfunction based on
these scales, there is a growing body of literature that is developing
to support the use of non-opioid pharmacotherapy [100] and the
psychosocial interventions [101], such as cognitive behavioral
therapy, mindfulness meditation and hypnotherapy to help address
these issues.
Discussion Question 7: Are abdominal imaging studies useful in
assessing pain in patients with chronic pancreatitis?
Statement: Abdominal imaging may be useful in identifying
pancreatic or biliary duct obstruction, inﬂammation, pseudocysts or
extrapancreatic complications that may direct speciﬁc treatments.
Evidence Level: 2b
Grade of recommendation: C
Level of Agreement: A 80%; B 18%; C 2%; D 0%; E 0%
Evidence and Discussion: A number of CP complications can
develop that cause or exacerbate pain. These include pseudocysts,pancreatic duct stones and strictures [102] which can be treated
with a reasonable expectation of relieving the pain. Therefore,
abdominal imaging studies are very important in identifying
structural abnormalities that may contribute to pain in some pa-
tients, even though images themselves cannot predict the presence,
type or pattern of pain [7].
A number of potentially useful imaging modalities are currently
available [103]. Abdominal imaging with either CT or MRI is widely
available and sensitive to detect complications of CP linked to
structural or density changes. EUS is also an established modality
for evaluation of CP [104]. These modalities should be used judi-
ciously and only when the results are expected to change or guide
further interventions.
Part 3. Management and treatment of pain in CP
Five discussion questions were developed.
Discussion Question 8: What should the initial management be
for pain in patients with uncomplicated chronic pancreatitis?
Guidance Statement: Medical management should be the ﬁrst
line of therapy for pain in uncomplicated CP. If present, psychiatric
disorders andmaladaptive coping strategies should be addressed in
conjunction with pain therapy.
Evidence Level: 1b
Grade of recommendation: B
Level of Agreement: A 65%; B 18%; C 8%; D 3%; E 6%
Evidence and Discussion: All patients with established CP
should be offered medical management for pain, when present.
Patients who have an inﬂammatory mass, pancreatic duct
obstruction secondary to a stricture and/or main duct stone(s), or
peripancreatic complications (e.g., pseudocyst) might require
additional treatment(s). Even in patients who appear appropriate
for endoscopic or surgical therapy, initial medical management of
pain is recommended to give relief, to better understand the pain
mechanism, responsiveness to treatment and whether there is a
signiﬁcant sensitization.
A stepwise approach should be used for analgesic medications
[17,106]. Non-narcotic analgesic medications (e.g. nonsteroidal
anti-inﬂammatory drugs [NSAIDS]) are the initial choice. Narcotic
medications should be considered in a patient who has constant
and/or severe pain not controlled with non-narcotic analgesics. The
initial choice of narcotic should be a weaker, mixed ago-
nisteantagonist or partial agonist (e.g. tramadol) before using
stronger narcotics (e.g. morphine, hydrocodone and hydro-
morphone). Patients who are expected to require long-term
narcotic analgesia for pancreatic pain are most appropriately
evaluated and managed in a Pain Clinic. A neuromodulating agent
(e.g. pregabalin) should be considered in a patient who requires
narcotic analgesics on a regular basis [10].
There is no deﬁnitive evidence that pancreatic enzyme
replacement therapy (PERT) provide general pain relief in CP [107].
However, for initial medical management, oral pancreatic enzyme
supplements in adequate doses and with rapid release have been
shown to provide some pain relief, possibly by providing negative
feedback inhibition of pancreatic secretion in early disease [41]. In
advanced CP with pancreatic exocrine insufﬁciency, PERT may
provide relief from symptoms of maldigestion [40]. Pancreatic
enzyme replacement therapy in patients with CP can reduce the
extent of steatorrhea and possibly pain, but also other symptoms
that impact a patient's QoL [18,108e110].
The role of antioxidants inmanagement of pain in CP is debatable
[111,112]; there is some evidence of a beneﬁt in a subset of patients
with idiopathic CP, but not in patients with alcoholic CP [113]. Some
M.A. Anderson et al. / Pancreatology 16 (2016) 83e9488studies show a trend towards some pain relief, and more so with a
combination of antioxidants rather than with single agents [114].
Recent meta-analyses also suggest that antioxidants can provide
marginal pain relief [115,116]. The challenge with the meta-analysis
is that the studies were from different populations, different
etiologies, different formulations, and may have other major con-
founding variables. Thus, antioxidant therapy is not routinely rec-
ommended in themanagement of pain associatedwith CP, but there
may be a role in some cases, such as idiopathic CP [113].
If medical treatment is ineffective within a given, limited time
period, or if endoscopic and/or surgical therapy are indicated, these
more invasive treatments should not be unduly delayed in hopes of
“spontaneous” pain relief over time [117]. Patients who have failed
or refused endoscopic or surgical therapy should be continued on
the most effective medical approaches. In the appropriate setting
patients should also undergo evaluation for TPIAT [15], as discussed
below.
Discussion Question 9: Does behavior modiﬁcation (cessation
of alcohol consumption and smoking) help in providing pain relief
in chronic pancreatitis?
Guidance Statement: Cessation of alcohol consumption and
smoking may help in providing pain relief.
Evidence Level: 2b
Grade of recommendation: C
Level of Agreement. A 49%; B 27%; C 19%; D 5%; E 0%
Evidence and Discussion: There are no data speciﬁcally eval-
uating the role of alcohol abstinence and smoking cessation in
improving the severity of CP related pain. However, continued
alcohol consumption and smoking increases the risk of recurrent
attacks of pancreatitis and disease progression [118e120]. A ran-
domized trial in patients with alcoholic acute pancreatitis
demonstrated beneﬁt of repeated counseling against alcohol con-
sumption in reducing the risk of recurrent attacks of pancreatitis
and hospitalizations [121]. It is recommended in several review
articles that counseling by certiﬁed therapists is indicated for
alcohol abstinence and smoking cessation in all patients with CP
and irrespective of the presence or severity of pain [122,123].
Discussion Question 10: What are the indications for endo-
scopic therapy for pain in chronic pancreatitis?
Guidance Statement: Patients who have symptomatic pancre-
atic ductal dilatation and/or stricture(s) with/without intraductal
stone(s), pseudocysts or leaks are candidates for endoscopic
therapy.
Evidence Level: 2b
Grade of recommendation: B
Level of Agreement: A 86%; B 7%; C 3%; D 2%; E 2%
Evidence and Discussion: Endoscopic therapy plays an impor-
tant role in the treatment of CP associated pain [19]. Because the
cause of pain is multifactorial not all patients will respond to
endoscopic treatment, even when technically successful. It was the
opinion of members of the working group that endoscopic treat-
ment should be performed by individuals with speciﬁc interest and
expertise in this area.
The working group believes that the best candidates for
endoscopic treatment are those with signiﬁcant pain from ductal
obstruction identiﬁed by cross-sectional abdominal imaging,
especially dominant strictures in the head of the pancreas. Endo-
scopic therapy may also be useful for some patients with biliary
obstruction, pancreatic pseudocysts, pancreatic ﬁstula, pancreatic
duct strictures and those with pancreatic duct calculi who might
respond to extracorporeal shockwave lithotripsy (ESWL).ESWL has an important role in management of pain in patients
with CP. At selected centers with a large experience, ESWL of large
(5 mm or greater) pancreatic stones can achieve clearance in
approximately 75% of patients undergoing multiple sessions, and
treatment was associated with signiﬁcant pain relief [124]. In a
randomized trial, ESWL without ERCP for ductal clearance was
found to be as effective and more cost effective than the routine
combination of ESWL with ERCP and ductal clearance of stones and
debris [125].
Pancreatic ductal strictures most amenable to endoscopic
therapy are those in the pancreatic head, rather than the body and
tail. There is a large literature giving evidence that pancreatic duct
stenting is effective for symptomatic ductal obstruction in the
setting of CP [126e129], even though there are no randomized,
blinded, sham-controlled studies in this setting. Sphincterotomy,
stricture dilation, and large caliber plastic stenting with one or
more 7e10 French gauge stents for a prolonged period of time (for
3e12 months) appears to be most beneﬁcial [130]. The use of
multiple large plastic stents and expandable metal mesh stents
(SEMS) in the pancreatic duct remains experimental and cannot yet
be considered standard of care.
The utility of endoscopic vs. surgical approaches in treating pain
continues to be debated. Two randomized trials [131,132], including
one with long-term follow-up, have compared endoscopic and
surgical treatment. The evidence indicates that surgery provides
superior pain relief (80 vs. 38%) in the short (2 years) and long (6
years) term. Patients assigned to endoscopic treatment had more
procedures and approximately half of these eventually had surgical
treatment. However, concern has been expressed that this study
did not compare ‘like-with-like’. A highly selected group under-
going surgery was compared to patients were likely to have a poor
outcome from endotherapy (e.g. those with disease in the body and
tail and those with a heavy ductal stone burden) [133]. Thus, the
working group believes that additional studies are needed to
determine optimal utility of endoscopic and surgical approaches to
treating pain in patients with CP.
Analysis of NAPS2 patients who had long-term follow-up at the
University of Pittsburgh provides a perspective on current clinical
practice in an expert center [11]. Patients who were selected for
endoscopic therapy if it was considered that the etiology of pain or
RAP was obstructive in nature. Endoscopic therapy was clinically
successful for 50% of patients with symptomatic CP, deﬁned by
cessation of narcotic therapy and resolution of RAP. When endo-
scopic was not successful, an additional 50% of the remaining pa-
tients had long-term relief with surgery [11].
Endoscopic treatment is still used as a ﬁrst line therapy in many
centers and continues to be recommended by endoscopy societies
[19]. Justiﬁcation for primary endoscopic treatment is made on the
basis of it being less invasive, less expensive and more readily
available. In select patients, surgery should be considered the ﬁrst
approach. These include patients who have a heavy stone burden
especially in the body/tail of the pancreas with pancreatic ductal
dilatation and/or strictures [131,132], and those with an inﬂam-
matory mass (where the primary etiology of pain is not likely to be
duct obstruction). However, some patients may decline surgery, are
too high risk for surgery or may improve sufﬁciently following
initial endoscopic therapy to not require a deﬁnitive surgical
approach [11]. If patients do not signiﬁcantly improve following
endoscopic therapy and they are surgical candidates, then surgical
treatment should not be delayed [117].
Most symptomatic pancreatic pseudocysts can be treated
endoscopically. Transmural endoscopic drainage under endoscopic
ultrasound guidance with Doppler signal can be attempted where
expertise is available. While not more effective than surgery, it is
less invasive and expensive [134]. Pancreatography at the time of
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including the location of strictures and leaks [135]. In patients with
a disconnected duct syndrome, a pseudocyst and proximal duct
dilatation, especially when there are intraductal calculi and/or
strictures, surgical decompression of the pseudocyst with duct
clearance may be indicated to address pain. Pancreatic ductal leaks
may cause a pseudocyst and/or ﬁstulae, and can sometimes be
treated with transpapillary pancreatic duct stenting [136e138]. If
the leak is associated with a high-grade proximal strictures and/or
calculi then treatment of this obstruction with transpapillary
stenting may lead to resolution.
Biliary obstruction from CP may result in abdominal pain but
more commonly jaundice or cholestasis. In the short-term, bile
duct stenting should be performed particularly to relieve jaundice,
cholangitis or severe pruritus. Recent studies suggest that covered
expandable metal stents (SEMS) may be a viable management
option, although multiple plastic stents can provide better long-
term relief [139]. However, longer term follow-up data is
required. Patients with signiﬁcant calciﬁcations of the pancreatic
head may be those less likely to beneﬁt from stenting in the long-
term. Surgical biliary bypass by Roux en Y hepaticojejunostomy is a
deﬁnitive treatment, yields excellent durable results and should be
considered in the ﬁt patient [140,141]. However, hep-
atojejunostomy is not without problems, and rarely can result in an
anastomotic stricture and this promotes secondary biliary cirrhosis
[142]. This can be combined with decompressive pancreato-
jejunostomy if indicated.
Neurolytic therapies to treat CP can be done using a variety of
techniques, including EUS-guided [143], radiology image guided
and surgical treatments. At this time, the use of EUS-guided CPB
(celiac plexus block) cannot be recommended as routine therapy
for pain in CP since only one-half of the patients experience pain
reduction and the beneﬁcial effect tends to be short lived [143]. A
recent randomized controlled trial showed that adding steroids to
bupivacaine in celiac plexus block was no more effective than
placebo plus bupivacaine and both groups had an overall very poor
response [144]. Surgical division of the splanchnic nerves in the
chest (thoracic splanchnicectomy) yields similar short-term, vari-
able responses and thus cannot be routinely recommended [145].
Discussion Question 11: What are the indications for surgery
(resection or drainage procedure) for pain in chronic pancreatitis?
Guidance Statement A: Surgery by resection or drainage is
indicated in patients with persistent chronic pancreatitis pain that
fails to respond to medical and/or endoscopic therapy.
Evidence Level: 2b
Grade of recommendation: C
Level of Agreement: A 67%; B 27%; C 6%; D 0%; E 0%
Guidance Statement B: Pancreatic resection or drainage pro-
cedures (e.g. lateral pancreatico-jejunostomy) should not be per-
formed in patients who are candidates for total pancreatectomy
and islet autotransplantation (TPIAT) in settings where this is
available, as this can result in a low yield of islets.
Evidence Level: 2b
Grade of recommendation: C
Level of Agreement: A 100%; B 0%; C 0%; D 0%; E 0%
Evidence and Discussion: Multiple clinical studies provide ev-
idence that surgery is a more effective long-term therapy for pain in
patients with CP than endoscopic or other treatments [131,132].
Among patients with pancreatic pain, surgery is the most effective
when the etiology of pain is obstructive, typically with signiﬁcant
post-prandial pain exacerbations and a dilated main pancreaticduct [146]. Surgery, rather than endoscopic therapy should be
considered in patients who have a heavy stone burden, especially in
the body/tail of the pancreas with pancreatic ductal dilatation and/
or strictures. Endotherapy may be useful as a bridge to surgical
treatment for those patients who are candidates for surgery, but
who are initially unﬁt [147].
The timing of surgical intervention is an important factor in
clinical outcomes; surgery has been shown to be most successful
when performed within three years of symptom onset but the
development of central pain is a concern when surgical interven-
tion is deferred [11,146] The probability of long-term pain relief
from surgery can be estimated on the basis of the duration of pain,
use of preoperative opioids, and the number of endoscopic in-
terventions [116].
There is a range of surgical options, including resection,
decompression and a combination of these [148], as well as TPIAT
as reviewed by Bellin et al. [15]. Among drainage procedures,
patients with a dilated main duct and without an inﬂammatory
mass in the head of the pancreas are best managed with decom-
pression of the duct (longitudinal pancreatico-jejunostomy) and
with either coring of the head (Frey procedure) or resection of the
head (Beger procedure) [148]. Patients with an inﬂammatory
mass in the head of the pancreas, especially if malignancy cannot
be excluded, will require pancreatic head resection (Whipple's
procedure), with or without pancreatic duct decompression. Pa-
tients with obstructive jaundice secondary to a benign distal
biliary stricture may beneﬁt from a Roux-en-Y hepatico-jejunos-
tomy at the same time. Patients with non-alcoholic etiologies of
CP may do well with TPIAT, but pain relief and outcomes are not as
good for patients with an alcohol etiology [15,149,150]. Recom-
mendations for the evaluation, treatment and follow-up of pa-
tients who may be candidates for TPIAT were recently published
[15].
There are data suggesting that drainage of a dilated pancreatic
duct delays functional deterioration and disease progression in
patients with mild-moderate CP and minimal pain [117,151]. This
approach has not been widely implemented and patient selection
must take into account comorbidities, ongoing substance use and a
discussion with the patient by a surgeon about the risks and ben-
eﬁts of surgery.
Prospective randomized trials of pancreatico-duodenectomy
(Whipple procedure), the duodenum-preserving pancreatic head
resection (Beger procedure), and the local resection of the
pancreatic head with longitudinal pancreatico-jejunostomy (Frey
procedure) indicate equivalent degrees of pain relief (70e80%) in
both the short and long term [28,152]. The Frey procedure has a
lower risk of peri-operative and post-operative complications and
has become the preferred procedure by many pancreatic surgeons.
The principal short-coming of the lateral pancreatico-jejunostomy
(Puestow) procedure is the risk of recurrent symptoms due to
progressive inﬂammation localized to the pancreatic head [153].
Just draining a dilated duct (lateral pancreatico-jejunostomy) is no
longer considered the standard of care for the treatment of pain
associated with obstructive pancreatopathy.
TPIAT is a new, and debated approach to management of
intractable pain in patients with impaired quality of life due to CP or
RAP in whom medical, endoscopic, or prior surgical therapy have
failed [15]. Because islet isolation requires a special facility and is
technically challenging, it is only offered at a limited number of
centers, primarily in the United States. Delay in referral of patients
for TPIAT that results in progressive ﬁbrosis and loss of islet cells,
proceeding with pancreatic resections, or performing some
drainage procedures markedly reduce islet yield [149,156]. On the
other hand, many CP patients, especially with more advanced dis-
ease, may be better served with more traditional approaches.
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pain be assessed?
Guidance Statement: A combination of objective ﬁndings
should be used to assess treatment response of therapies over time
including use of serial validated pain scores, quality of life (QOL)
instruments, pain medication use, frequency of pain episodes,
hospitalizations and emergency room visits.
Evidence Level: 2b
Grade of recommendation: B
Level of Agreement: A 93%; B 5%; C: 2%; D 0%; E 0%
Evidence and Discussion: Current tools to predict the response
to all forms of therapies (medical, endoscopic, surgery) are inade-
quate and new ones need to be developed. There are limited data
correlating the response to therapies with different pain
mechanisms.
Pain will not consistently improve with endoscopic or surgical
drainage of a dilated pancreatic duct or with resection of inﬂamed
parenchyma. This reinforces that pain mechanisms in CP are
complex and may be modulated by multiple and differing path-
ways during evolution of the disease.
A variety of methods have been used to assess the outcome of
intervention for pain and QOL in CP, as reviewed in Discussion
Questions 4 to 6. Placebo controlled trials are rare in CP but do
suggest a low rate of response of approximately 20% [64]. The
expectation of spontaneous abatement of pain (burn out) in CP,
suggested by some [157] and found to be uncommon by others
[100], has resulted in undue patient suffering and been a disin-
centive to long-term, non-placebo-controlled studies. It appears
that the frequency and severity of pain does not correlate with the
duration of CP [1], but is affected by multiple disease-modifying
factors. Some centers are using a systematic mechanism-oriented
approach to pain in CP by applying tools such as quantitative sen-
sory testing, electroencephalography and functional magnetic
resonance imaging to address central pain, but this approach has
not been proven to be superior to current approaches and requires
further study [18]. Regardless of method, systematic assessment of
pain character, pattern and severity must be monitored for long
periods of time so that the effectiveness of interventions can by
accurately assessed.
Research recommendations
Disease mechanisms
A major research effort is needed to identify sensitive and
speciﬁc biomarkers that link pain mechanisms with clinical fea-
tures. The relationship between local and central pain should be
clariﬁed in terms of context, timing and clinical features. The
development of better techniques to study central pain in humans
and experimental models is critical for addressing this issue.
Although neuropathology is often evident in human pancreatic
tissue samples, the clinical context and associated pain phenotypes
have not yet been identiﬁed. Thus, neuropathic biology, the clinical
context and speciﬁc consequences are not easily identiﬁed and
treated by clinicians. Further studies are needed to determine
whether speciﬁc neuropathologies, such as neuroinﬂammation or
direct nerve injury, are associated with distinct clinical conse-
quences. The relationship between normal and abnormal re-
sponses to pancreatic stress or injury must also be clariﬁed,
especially in relation to genetic and environmental modiﬁers,
including medications. Mechanistic pathways, speciﬁc risk factors,
other variables and better biomarker linking the syndrome of
constant pain to the underlying pathologic processes in individual
patients are needed.Assessment of pain
Although multiple possible mechanisms of pain have been
described, there are few, if any, well-validated instruments that
discriminate between pain features and mechanisms. Large, well-
controlled, long-term trials are needed to deﬁne the natural his-
tory of pain and to evaluate a range of pain assessment instruments.
These studies should include comprehensive evaluation of each
patient to determine the relative contribution and potential syn-
ergy of active inﬂammation, obstruction, tissue hypertension or
ischemia, neuropathy, centralization, mental health and comor-
bidities. Speciﬁc comorbidities include extra-pancreatic pain, gas-
troparesis, dysmotility, diabetes mellitus, broader pain syndromes
and complications of treatments such as narcotic bowel syndrome.
The role of emotional and mental health, including anxiety and
depression, must be included in pain evaluations. The effects of
perceived symptoms and responses to therapy should be applied to
these assessments.
Management and treatment of pain
Better methods that speciﬁcally target pain mechanisms must
be developed along with guidance onwhich patient types are likely
to respond. The indications for the primary use of endoscopic or
surgical therapy for speciﬁc patient populations must be resolved.
Guidance on the individual risk and time window needed to pre-
vent pain sensitization is needed. Pain management should also
monitor each active pain mechanism so that the effectiveness of
each treatment approach can be monitored, and new problems
detected early. The responses to intervention, whether medical,
surgical or experimental, should be documented using validated
tools in systematic ways for ongoing evaluation. Patients under-
going TPIAT should be studied in a longitudinal and systematic way
before and after surgery, and the tissue evaluated to better un-
derstand local and central pain mechanisms in speciﬁc disease
states.
Summary
Pain is the foremost problem in CP, and a major source of
morbidity and decreased QOL for affected patients. Future studies
to further elucidate the link between clinical signs and symptoms of
CP, patient pain phenotypes, neuropathologic features and genetic
and environmental inﬂuences are critical for the development of
new, more effective treatment strategies. New tools for ongoing
assessment of pain and pain mechanisms are necessary for un-
derstanding the natural history and for effectiveness of treatments
in future clinical trials. The complexity of pancreatic pain is clearly
one clinical problem that would greatly beneﬁt from a robust dia-
logue between clinicians and basic science pain researchers. Only
by understanding the mechanisms contributing to the various
presentations of pancreatic pain will it be possible to identify the
most efﬁcacious treatments with the minimum of complications
and improvement of the quality of life of the affected patients.
Author contributions
Developed the concept and the consensus process: M.A.A., K.M.A.,
R.E.B., L.F., and D.C.W.
Pancreas Pain working groups: M.A.A. (chair), K.M.A., S.T.A., I.B.,
S.C., G.C., B.M.D, A.G., N.G., A.H., R.L., A.S, R.S.G., E.S., W.W., C.M.W,
J.W., and D.Y.
Wrote the Manuscript: D.C.W. (senior author), M.A.A., V.A.,
K.M.A., S.T.A., I.B., B.M.D., R.S.G., E.S., J.T., W.W., C.M.W., J.W., D.Y.
Participated in discussion of statements, reviewed and approved
manuscript. All authors and participants.
M.A. Anderson et al. / Pancreatology 16 (2016) 83e94 91Review and analysis of the evidence on the mechanisms of pain
in CP was led by Co-chairs Kathryn Albers PhD and Inna Belfer MD
PhD, with committee members Suresh Chari MD, Greg Cote MD
MSc, Brian Davis PhD, Roger Liddle MD, and Rachelle Gupta MD,
PhD.
The review and analysis of the evidence on the assessment of
pain in CP and affects on QOL was led by Co-chairs Michelle
Anderson MD and Wahid Wassef MD MPH, with committee
members Stephen AmannMD, Eva Szigethy MD PhD, C. Mel Wilcox
MD, Dhiraj Yadav MD MPH.
Review and analysis of the management and treatment of pain
in CP was led by Co-chairs C. Mel Wilcox MD and Dhiraj Yadav MD
MPH., with committee members Andres Gelrud MD, Abhinav
Humar MD, Adam Slivka MD PhD, John Windsor MBChB, MD.
Acknowledgments
This work was supported in part by conference grants from the
NIDDK (DK09690; DK100242; DK103527; DK098560), CME pro-
grams through the University of Pittsburgh ofﬁce of Continuing
Medical Education and a gift to UPMC from AbbVie to improve
patient care.
Appendix. Consensus development participants
A. Listed as authors who participated in the guidance conference
for pain and critically reviewed the paper.
Dana K. AndersenMD (NIDDK, NIH, Bethesda, (MD)), John Baillie
MD (Richmond, VA)), Marie Cook, RN, CNP, MPH, CCTC (Fairview
Health Services (MN)), Melena Bellin, MD.
University of Minnesota Medical Center (MN)), Kathryn Berry
RN (University of Minnesota Medical Center (MN)), Lisa Bocelli DO
(University of Massachusetts (Worcester, MA)), Randall E. Brand
MD (University of Pittsburgh (PA)), Jennifer Chennat MD (Univer-
sity of Pittsburgh Medical Center (PA)), John F. Eisses, M.D. Ph.D.
(Children's Hospital of Pittsburgh of UPMC (AP)), Luca Frulloni MD
(University of Verona (Verona, Italy)), Vay Liang Go MD (University
of California at Los Angeles (CA)), Julia B. Greer MDMPH (University
of Pittsburgh (PA)), Michael A Hollingsworth PhD (University of
Nebraska Medical Center (NE)), Sohail Husain MD (UPMC Chil-
dren's Hospital of Pittsburgh (PA)), Kyung Mo Kim MD (Asan
Medical Center Children's Hospital/Korea), Louis Lambiase MD
(Chattanooga (TN)), Mark E. Lowe MD PhD (Children's Hospital of
Pittsburgh of UPMC (PA)), Markus M. Lerch MD (University Medi-
cine Greifswald, Germany), Veronique Morinville MD (Montreal
Children's Hospital (Canada)), Thiruvengadam Muniraj MD PhD
(Yale University, New Haven (CT)), Joseph Palermo MD PhD (Uni-
versity of Cincinnati Children's Hospital (OH))Walter Park MD
(Stanford University (Stanford, CA)), Mordechai Rabinovitz, M.D.
(University of Pittsburgh (PA)), Michael R Rickels MD MS (Univer-
sity of Pennsylvania Perelman School of Medicine (PA)), Bimaljit
Sandhu MD DM (St Mary's Hospital, (Richmond, VA), Sarah Jane
Schwarzenberg MD (University of Minnesota Masonic Children's
Hospital (MN)). Seth Sclair MD (University of Miami Miller School
of Medicine (Miami, FL)), Shalinender Singh MD (University of
Nebraska (NE)), Frederico G.S. Toledo, MD (University of
Pittsburgh (PA)), Aliye Uc MD (University of Iowa Hospitals and
Clinics (IA)).
References
[1] Mullady DK, Yadav D, Amann ST, O'Connell MR, Barmada MM, Elta GH, et al.
Type of pain, pain-associated complications, quality of life, disability and
resource utilisation in chronic pancreatitis: a prospective cohort study. Gut
2011;60(1):77e84. PMID: 21148579.[2] Amann ST, Yadav D, Barmada MM, O'Connell M, Kennard ED, Anderson M,
et al. Physical and mental quality of life in chronic pancreatitis: a case-
econtrol study from the North American Pancreatitis Study 2 cohort.
Pancreas 2013;42(2):293e300. PMID: 23357924.
[3] Pasricha PJ. Unraveling the mystery of pain in chronic pancreatitis. Nat Rev
Gastroenterol Hepatol 2012;9(3):140e51. PMID: 22269952.
[4] Whitcomb DC, Yadav D, Adam S, Hawes RH, Brand RE, Anderson MA, et al.
Multicenter approach to recurrent acute and chronic pancreatitis in the
United States: the North American Pancreatitis Study 2 (NAPS2). Pan-
creatology 2008;8(4e5):520e31. PMID: 18765957.
[5] Yadav D, Hawes RH, Brand RE, Anderson MA, Money ME, Banks PA, et al.
Alcohol consumption, cigarette smoking, and the risk of recurrent acute and
chronic pancreatitis. Arch Intern Med 2009;169(11):1035e45. PMID:
19506173.
[6] Frulloni L, Gabbrielli A, Pezzilli R, Zerbi A, Cavestro GM, Marotta F, et al.
Chronic pancreatitis: report from a multicenter Italian survey (Pan-
CroInfAISP) on 893 patients. Dig Liver Dis 2009;41(4):311e7. PMID:
19097829.
[7] Wilcox CM, Yadav D, Tian Y, Gardner TB, Gelrud A, Sandhu BS, et al. Chronic
pancreatitis pain pattern and severity are independent of abdominal imaging
ﬁndings. Clin Gastroenterol Hepatol 2014;13(3):552e60. PMID: 25424572.
[8] Mokrowiecka A, Pinkowski D, Malecka-Panas E, Johnson CD. Clinical,
emotional and social factors associated with quality of life in chronic
pancreatitis. Pancreatology 2010;10(1):39e46. PMID: 20332660.
[9] Graversen C, Olesen SS, Olesen AE, Steimle K, Farina D, Wilder-Smith OH,
et al. The analgesic effect of pregabalin in chronic pain patients is reﬂected by
changes in pharmaco-EEG spectral indices. Br J Clin Pharmacol 2011;73(3):
363e72. PMID: 21950372.
[10] Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM. Pre-
gabalin reduces pain in patients with chronic pancreatitis in a randomized,
controlled trial. Gastroenterology 2011;141(2):536e43. PMID: 21683078.
[11] Clarke B, Slivka A, Tomizawa Y, Sanders M, Papachristou GI, Whitcomb DC,
et al. Endoscopic therapy is effective for patients with chronic pancreatitis.
Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc
2012;10(7):795e802. PMID: 22245964.
[12] Issa Y, Bruno MJ, Bakker OJ, Besselink MG, Schepers NJ, van Santvoort HC,
et al. Treatment options for chronic pancreatitis. Nat Rev Gastroenterol
Hepatol 2014;11(9):556e64. PMID: 24912390.
[13] Blondet JJ, Carlson AM, Kobayashi T, Jie T, Bellin M, Hering BJ, et al. The role
of total pancreatectomy and islet autotransplantation for chronic pancrea-
titis. Surg Clin North Am 2007;87(6):1477e501. x. PMID: 18053843.
[14] Bellin MD, Freeman ML, Schwarzenberg SJ, Dunn TB, Beilman GJ, Vickers SM,
et al. Quality of life improves for pediatric patients after total pancreatec-
tomy and islet autotransplant for chronic pancreatitis. Clin Gastroenterol
Hepatol Off Clin Pract J Am Gastroenterol Assoc 2011;9(9):793e9. PMID:
21683160.
[15] Bellin MD, Freeman ML, Gelrud A, Slivka A, Clavel A, Humar A, et al. Total
pancreatectomy and islet autotransplantation in chronic pancreatitis: rec-
ommendations from PancreasFest. Pancreatology 2014;14(1):27e35. PMID:
24555976.
[16] Frulloni L, Falconi M, Gabbrielli A, Gaia E, Graziani R, Pezzilli R, et al. Italian
consensus guidelines for chronic pancreatitis. Dig Liver Dis Off J Ital Soc
Gastroenterol Ital Assoc Study Liver 2010;42(Suppl. 6):S381e406. PMID:
21078490.
[17] Mayerle J, Hoffmeister A, Werner J, Witt H, Lerch MM, Mossner J. Chronic
pancreatitis e deﬁnition, etiology, investigation and treatment. Dtsch Arz-
teblatt Int 2013;110(22):387e93. PMID: 23826027.
[18] Bouwense SA, de Vries M, Schreuder LT, Olesen SS, Frokjaer JB, Drewes AM,
et al. Systematic mechanism-orientated approach to chronic pancreatitis
pain. World J Gastroenterol WJG 2015;21(1):47e59. PMID: 25574079.
[19] Dumonceau JM, Delhaye M, Tringali A, Dominguez-Munoz JE, Poley JW,
Arvanitaki M, et al. Endoscopic treatment of chronic pancreatitis: European
Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. Endoscopy
2012;44(8):784e800. PMID: 22752888.
[20] Rickels MR, Bellin M, Toledo FG, Robertson RP, Andersen DK, Chari ST, et al.
Detection, evaluation and treatment of diabetes mellitus in chronic
pancreatitis: recommendations from PancreasFest 2012. Pancreatology
2013;13(4):336e42. PMID: 23890130.
[21] CEBM. Centre for Evidence-Based Medicine: levels of evidence. University of
Oxford; 2014 [cited 2014]. Available from: http://www.cebm.net/oxford-
centre-evidence-based-medicine-levels-evidence-march-2009/.
[22] Jaeschke R, Guyatt GH, Dellinger P, Schunemann H, Levy MM, Kunz R, et al.
Use of GRADE grid to reach decisions on clinical practice guidelines when
consensus is elusive. BMJ 2008;337:a744. PMID: 18669566.
[23] Ebbehoj N, Borly L, Madsen P, Svendsen LB. Pancreatic tissue pressure and
pain in chronic pancreatitis. Pancreas 1986;1(6):556e8. PMID: 3562446.
[24] Ebbehoj N, Borly L, Bulow J, Rasmussen SG, Madsen P, Matzen P, et al.
Pancreatic tissue ﬂuid pressure in chronic pancreatitis. Relation to pain,
morphology, and function. Scand J Gastroenterol 1990;25(10):1046e51.
PMID: 2263877.
[25] Karanjia ND, Reber HA. The cause and management of the pain of chronic
pancreatitis. Gastroenterol Clin North Am 1990;19(4):895e904. PMID:
2269524.
[26] Karanjia ND, Widdison AL, Leung F, Alvarez C, Lutrin FJ, Reber HA.
Compartment syndrome in experimental chronic obstructive pancreatitis:
M.A. Anderson et al. / Pancreatology 16 (2016) 83e9492effect of decompressing the main pancreatic duct. Br J Surg 1994;81(2):
259e64. PMID: 8156353.
[27] Renou C, Grandval P, Ville E, Laugier R. Endoscopic treatment of the main
pancreatic duct: correlations among morphology, manometry, and clinical
follow-up. Int J Pancreatol 2000;27(2):143e9. PMID: 10862513.
[28] Strate T, Bachmann K, Busch P, Mann O, Schneider C, Bruhn JP, et al.
Resection vs drainage in treatment of chronic pancreatitis: long-term results
of a randomized trial. Gastroenterology 2008;134(5):1406e11. PMID:
18471517.
[29] Dite P, Ruzicka M, Zboril V, Novotny I. A prospective, randomized trial
comparing endoscopic and surgical therapy for chronic pancreatitis.
Endoscopy 2003;35(7):553e8. PMID: 12822088.
[30] Winston JH, He ZJ, Shenoy M, Xiao SY, Pasricha PJ. Molecular and behavioral
changes in nociception in a novel rat model of chronic pancreatitis for the
study of pain. Pain 2005;117(1e2):214e22. PMID: 16098667.
[31] Hughes MS, Shenoy M, Liu L, Colak T, Mehta K, Pasricha PJ. Brain-derived
neurotrophic factor is upregulated in rats with chronic pancreatitis and
mediates pain behavior. Pancreas 2011;40(4):551e6. PMID: 21499209.
[32] Liu L, Shenoy M, Pasricha PJ. Substance P and calcitonin gene related peptide
mediate pain in chronic pancreatitis and their expression is driven by nerve
growth factor. JOP 2011;12(4):389e94. PMID: 21737902.
[33] Liddle RA, Nathan JD. Neurogenic inﬂammation and pancreatitis. Pan-
creatology 2004;4(6):551e9. discussion 9e60. PMID: 15550764.
[34] Xu GY, Winston JH, Shenoy M, Yin H, Pendyala S, Pasricha PJ. Transient re-
ceptor potential vanilloid 1 mediates hyperalgesia and is up-regulated in rats
with chronic pancreatitis. Gastroenterology 2007;133(4):1282e92. PMID:
17698068.
[35] Ceyhan GO, Deucker S, Demir IE, Erkan M, Schmelz M, Bergmann F, et al.
Neural fractalkine expression is closely linked to pain and pancreatic neuritis
in human chronic pancreatitis. Lab Investig 2009;89(3):347e61. PMID:
19153557.
[36] Di Sebastiano P, Fink T, Weihe E, Friess H, Innocenti P, Beger HG, et al. Im-
mune cell inﬁltration and growth-associated protein 43 expression correlate
with pain in chronic pancreatitis. Gastroenterology 1997;112(5):1648e55.
PMID: 9136844.
[37] Hoogerwerf WA, Gondesen K, Xiao SY, Winston JH, Willis WD, Pasricha PJ.
The role of mast cells in the pathogenesis of pain in chronic pancreatitis. BMC
Gastroenterol 2005;5:8. PMID: 15745445.
[38] Friess H, Ding J, Kleeff J, Liao Q, Berberat PO, Hammer J, et al. Identiﬁ-
cation of disease-speciﬁc genes in chronic pancreatitis using DNA array
technology. Ann Surg 2001;234(6):769e78. discussion 78e9. PMID:
11729383.
[39] Ceyhan GO, Bergmann F, Kadihasanoglu M, Altintas B, Demir IE, Hinz U, et al.
Pancreatic neuropathy and neuropathic pain e a comprehensive patho-
morphological study of 546 cases. Gastroenterology 2009;136(1):177e86.
e1. PMID: 18992743.
[40] Gubergrits N, Malecka-Panas E, Lehman GA, Vasileva G, Shen Y, Sander-
Struckmeier S, et al. A 6-month, open-label clinical trial of pancrelipase
delayed-release capsules (Creon) in patients with exocrine pancreatic
insufﬁciency due to chronic pancreatitis or pancreatic surgery. Aliment
Pharmacol Ther 2011;33(10):1152e61. PMID: 21418260.
[41] Slaff J, Jacobson D, Tillman CR, Curington C, Toskes P. Protease-speciﬁc
suppression of pancreatic exocrine secretion. Gastroenterology 1984;87(1):
44e52. PMID: 6202586.
[42] Ceppa E, Cattaruzza F, Lyo V, Amadesi S, Pelayo JC, Poole DP, et al. Transient
receptor potential ion channels V4 and A1 contribute to pancreatitis pain in
mice. Am J Physiol Gastrointest Liver Physiol 2010;299(3):G556e71. PMID:
20539005.
[43] Kawabata A, Matsunami M, Tsutsumi M, Ishiki T, Fukushima O, Sekiguchi F,
et al. Suppression of pancreatitis-related allodynia/hyperalgesia by
proteinase-activated receptor-2 in mice. Br J Pharmacol 2006;148(1):54e60.
PMID: 16520745.
[44] Schwartz ES, Christianson JA, Chen X, La JH, Davis BM, Albers KM, et al.
Synergistic role of TRPV1 and TRPA1 in pancreatic pain and inﬂammation.
Gastroenterology 2011;140(4):1283e91. e1e2. PMID: 21185837.
[45] Schwartz ES, La JH, Scheff NN, Davis BM, Albers KM, Gebhart GF. TRPV1 and
TRPA1 antagonists prevent the transition of acute to chronic inﬂammation
and pain in chronic pancreatitis. J Neurosci 2013;33(13):5603e11. PMID:
23536075.
[46] Feng QX, Wang W, Feng XY, Mei XP, Zhu C, Liu ZC, et al. Astrocytic activation
in thoracic spinal cord contributes to persistent pain in rat model of chronic
pancreatitis. Neuroscience 2010;167(2):501e9. PMID: 20149842.
[47] Liu PY, Lu CL, Wang CC, Lee IH, Hsieh JC, Chen CC, et al. Spinal microglia
initiate and maintain hyperalgesia in a rat model of chronic pancreatitis.
Gastroenterology 2012;142(1):165e73. e2. PMID: 21963786.
[48] Frokjaer JB, Bouwense SA, Olesen SS, Lundager FH, Eskildsen SF, van Goor H,
et al. Reduced cortical thickness of brain areas involved in pain processing in
patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2012;10(4):
434e8. e1. PMID: 22155560.
[49] Frokjaer JB, Olesen SS, Gram M, Yavarian Y, Bouwense SA, Wilder-Smith OH,
et al. Altered brain microstructure assessed by diffusion tensor imaging in
patients with chronic pancreatitis. Gut 2011;60(11):1554e62. PMID:
21610272.
[50] Baliki MN, Schnitzer TJ, Bauer WR, Apkarian AV. Brain morphological sig-
natures for chronic pain. PLoS One 2011;6(10):e26010. PMID: 22022493.[51] Dimcevski G, Sami SA, Funch-Jensen P, Le Pera D, Valeriani M, Arendt-
Nielsen L, et al. Pain in chronic pancreatitis: the role of reorganization in the
central nervous system. Gastroenterology 2007;132(4):1546e56. PMID:
17408654.
[52] Walker LS, Sherman AL, Bruehl S, Garber J, Smith CA. Functional abdominal
pain patient subtypes in childhood predict functional gastrointestinal dis-
orders with chronic pain and psychiatric comorbidities in adolescence and
adulthood. Pain 2012;153(9):1798e806. PMID: 22721910.
[53] Elsenbruch S. How positive and negative expectations shape the experi-
ence of visceral pain. Handb Exp Pharmacol 2014;225:97e119. PMID:
25304528.
[55] Young EE, Lariviere WR, Belfer I. Genetic basis of pain variability: recent
advances. J Med Genet 2012;49(1):1e9. PMID: 22058430.
[56] Nielsen CS, Knudsen GP, Steingrimsdottir OA. Twin studies of pain. Clin
Genet 2012;82(4):331e40. PMID: 22823509.
[57] Colucci R, Gambaccini D, Ghisu N, Rossi G, Costa F, Tuccori M, et al. Inﬂuence
of the serotonin transporter 5HTTLPR polymorphism on symptom severity in
irritable bowel syndrome. PLoS One 2013;8(2):e54831. PMID: 23393559.
[58] Kushnir VM, Cassell B, Gyawali CP, Newberry RD, Kibe P, Nix BD, et al. Ge-
netic variation in the beta-2 adrenergic receptor (ADRB2) predicts functional
gastrointestinal diagnoses and poorer health-related quality of life. Aliment
Pharmacol Ther 2013;38(3):313e23. PMID: 23786226.
[62] Whitcomb DC. Framework for interpretation of genetic variations in
pancreatitis patients. Front Physiol 2012;3:440. PMID: 23230421.
[64] Capurso G, Cocomello L, Benedetto U, Camma C, Delle Fave G. Meta-analysis:
the placebo rate of abdominal pain remission in clinical trials of chronic
pancreatitis. Pancreas 2012;41(7):1125e31. PMID: 22513290.
[66] Grimmer-Somers K, Vipond N, Kumar S, Hall G. A review and critique of
assessment instruments for patients with persistent pain. J Pain Res 2009;2:
21e47. PMID: 21197292.
[70] Gallagher EJ, Liebman M, Bijur PE. Prospective validation of clinically
important changes in pain severity measured on a visual analog scale. Ann
Emerg Med 2001;38(6):633e8. PMID: 11719741.
[72] Cook KF, Schalet BD, Kallen MA, Rutsohn JP, Cella D. Establishing a common
metric for self-reported pain: linking BPI pain interference and SF-36 bodily
pain subscale scores to the PROMIS pain interference metric. Qual life Res Int
J Qual Life Aspects Treat Care Rehabil 2015;16(1):87e101. PMID: 25894063.
[73] Wehler M, Reulbach U, Nichterlein R, Lange K, Fischer B, Farnbacher M, et al.
Health-related quality of life in chronic pancreatitis: a psychometric
assessment. Scand J Gastroenterol 2003;38(10):1083e9. PMID: 14621285.
[74] Gardner TB, Kennedy AT, Gelrud A, Banks PA, Vege SS, Gordon SR, et al.
Chronic pancreatitis and its effect on employment and health care experi-
ence: results of a prospective American multicenter study. Pancreas
2010;39(4):498e501. PMID: 20118821.
[75] Eisen GM, Zubarik R. Disease-speciﬁc outcomes assessment for chronic
pancreatitis. Gastrointest Endosc Clin N Am 1999;9(4):717e30. ix. PMID:
10495236.
[76] Fitzsimmons D, Kahl S, Butturini G, van Wyk M, Bornman P, Bassi C, et al.
Symptoms and quality of life in chronic pancreatitis assessed by structured
interview and the EORTC QLQ-C30 and QLQ-PAN26. Am J Gastroenterol
2005;100(4):918e26. PMID: 15784041.
[77] Pezzilli R, Morselli-Labate AM, Frulloni L, Cavestro GM, Ferri B, Comparato G,
et al. The quality of life in patients with chronic pancreatitis evaluated using
the SF-12 questionnaire: a comparative study with the SF-36 questionnaire.
Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 2006;38(2):
109e15. PMID: 16243011.
[78] Pezzilli R, Morselli-Labate AM, Fantini L, Campana D, Corinaldesi R. Assess-
ment of the quality of life in chronic pancreatitis using Sf-12 and EORTC Qlq-
C30 questionnaires. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study
Liver 2007;39(12):1077e86. PMID: 17692582.
[79] Pezzilli R, Morselli Labate AM, Fantini L, Gullo L, Corinaldesi R. Quality of life
and clinical indicators for chronic pancreatitis patients in a 2-year follow-up
study. Pancreas 2007;34(2):191e6. PMID: 17312457.
[80] Wassef W, Bova C, Barton B, Hartigan C. Pancreatitis quality of life instru-
ment: development of a new instrument. SAGE Open Med 2014;2:1e13
(2050312114520856) [PMID].
[81] Wassef W, DeWitt J, Wilcox M, Whitcomb DC, Yadav D, Amann s, et al.
Pancreatitis quality of life instrument (PANQOLI): a psychometric evaluation.
Am J Gastroenterol 2012;107(S79). PMID.
[82] Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, Cella D, et al. Identi-
fying important outcome domains for chronic pain clinical trials: an
IMMPACT survey of people with pain. Pain 2008;137(2):276e85. PMID:
17937976.
[83] Outcalt SD, Kroenke K, Krebs EE, Chumbler NR, Wu J, Yu Z, et al. Chronic pain
and comorbid mental health conditions: independent associations of post-
traumatic stress disorder and depression with pain, disability, and quality of
life. J Behav Med 2015;38(3):535e43. PMID: 25786741.
[84] Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of
chronic nonmalignant pain patients exposed to chronic opioid analgesic
therapy develop abuse/addiction and/or aberrant drug-related behaviors? A
structured evidence-based review. Pain Med 2008;9(4):444e59. PMID:
18489635.
[85] McCabe SE, Boyd CJ, Cranford JA, Morales M, Slayden J. A modiﬁed version of
the drug abuse screening test among undergraduate students. J Subst Abuse
Treat 2006;31(3):297e303. PMID: 16996392.
M.A. Anderson et al. / Pancreatology 16 (2016) 83e94 93[86] Connor JP, Grier M, Feeney GF, Young RM. The validity of the brief Michigan
alcohol screening test (bMAST) as a problem drinking severity measure.
J Stud Alcohol Drugs 2007;68(5):771e9. PMID: 17690811.
[87] Roelofs J, McCracken L, Peters ML, Crombez G, van Breukelen G, Vlaeyen JW.
Psychometric evaluation of the pain anxiety symptoms scale (PASS) in
chronic pain patients. J Behav Med 2004;27(2):167e83. PMID: 15171105.
[88] Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merriﬁeld T, Grittmann L. The
pain catastrophizing scale: further psychometric evaluation with adult
samples. J Behav Med 2000;23(4):351e65. PMID: 10984864.
[89] Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development
and validation. Psychol Assess 1995;7(4):524e32. PMID.
[90] Skinner HA. The drug abuse screening test. Addict Behav 1982;7(4):363e71.
PMID: 7183189.
[96] Turk DC, Burwinkle T. Clinical outcomes, cost-effectiveness, and the role of
psychology in treatments for chronic pain sufferers. J Psychol Res Pract
2005;36:602e10. PMID.
[97] Gagnon CM, Stanos SP, van der Ende G, Rader LR, Harden RN. Treatment
outcomes for workers compensation patients in a U.S.-based interdisci-
plinary pain management program. Pain Pract Off J World Inst Pain
2013;13(4):282e8. PMID: 22863287.
[98] Flor H, Fydrich T, Turk DC. Efﬁcacy of multidisciplinary pain treatment
centers: a meta-analytic review. Pain 1992;49(2):221e30. PMID: 1535122.
[99] Turk DC. Clinical effectiveness and cost-effectiveness of treatments for pa-
tients with chronic pain. Clin J Pain 2002;18(6):355e65. PMID: 12441829.
[100] Tornblom H, Drossman DA. Centrally targeted pharmacotherapy for chronic
abdominal pain. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc
2015;27(4):455e67. PMID: 25651186.
[101] Palsson OS, Whitehead WE. Psychological treatments in functional gastro-
intestinal disorders: a primer for the gastroenterologist. Clin Gastroenterol
Hepatol 2013;11(3):208e16. quiz e22e3. PMID: 23103907.
[102] Andren-Sandberg A, Hoem D, Gislason H. Pain management in chronic
pancreatitis. Eur J Gastroenterol Hepatol 2002;14(9):957e70. PMID:
12352215.
[103] Choueiri NE, Balci NC, Alkaade S, Burton FR. Advanced imaging of chronic
pancreatitis. Curr Gastroenterol Rep 2010;12(2):114e20. PMID:
20424983.
[104] Stevens T. Role of endoscopic ultrasonography in the diagnosis of acute and
chronic pancreatitis. Gastrointest Endosc Clin N Am 2013;23(4):735e47.
PMID: 24079787.
[106] World_Health_Organization. Traitement de la douleur cancereuse. Geneva,
Switz: World Health Organization; 1997.
[107] Winstead NS, Wilcox CM. Clinical trials of pancreatic enzyme replacement
for painful chronic pancreatitis e a review. Pancreatology 2009;9(4):
344e50. PMID: 19451744.
[108] Czako L, Takacs T, Hegyi P, Pronai L, Tulassay Z, Lakner L, et al. Quality of life
assessment after pancreatic enzyme replacement therapy in chronic
pancreatitis. Can J Gastroenterol J Can Gastroenterol 2003;17(10):597e603.
PMID: 14571298.
[109] D'Haese JG, Ceyhan GO, Demir IE, Layer P, Uhl W, Lohr M, et al. Pancreatic
enzyme replacement therapy in patients with exocrine pancreatic insufﬁ-
ciency due to chronic pancreatitis: a 1-year disease management study on
symptom control and quality of life. Pancreas 2014;43(6):834e41. PMID:
24717829.
[110] Whitcomb DC, Lehman GA, Vasileva G, Malecka-Panas E, Gubergrits N,
Shen Y, et al. Pancrelipase delayed-release capsules (CREON) for exocrine
pancreatic insufﬁciency due to chronic pancreatitis or pancreatic surgery: a
double-blind randomized trial. Am J Gastroenterol 2010;105(10):2276e86.
PMID: 20502447.
[111] Bhardwaj P, Garg PK, Maulik SK, Saraya A, Tandon RK, Acharya SK.
A randomized controlled trial of antioxidant supplementation for pain relief
in patients with chronic pancreatitis. Gastroenterology 2009;136(1):149e59.
e2. PMID: 18952082.
[112] Siriwardena AK, Mason JM, Sheen AJ, Makin AJ, Shah NS. Antioxidant therapy
does not reduce pain in patients with chronic pancreatitis: the ANTICIPATE
study. Gastroenterology 2012;143(3):655e63. e1. PMID: 22683257.
[113] Burton F, Alkaade S, Collins D, Muddana V, Slivka A, Brand RE, et al. Use and
perceived effectiveness of non-analgesic medical therapies for chronic
pancreatitis in the United States. Aliment Pharmacol Ther 2011;33(1):
149e59. PMID: 21083584.
[114] Cai GH, Huang J, Zhao Y, Chen J, Wu HH, Dong YL, et al. Antioxidant therapy
for pain relief in patients with chronic pancreatitis: systematic review and
meta-analysis. Pain Phys 2013;16(6):521e32. PMID: 24284838.
[115] Zhou D, Wang W, Cheng X, Wei J, Zheng S. Antioxidant therapy for patients
with chronic pancreatitis: a systematic review and meta-analysis. Clin Nutr
2014;34(4):627e34. PMID: 25035087.
[116] Ahmed Ali U, Jens S, Busch OR, Keus F, van Goor H, Gooszen HG, et al. An-
tioxidants for pain in chronic pancreatitis. Cochrane Database Syst Rev
2014;8:CD008945. PMID: 25144441.
[117] Yang CJ, Bliss LA, Schapira EF, Freedman SD, Ng SC, Windsor JA, et al. Sys-
tematic review of early surgery for chronic pancreatitis: impact on pain,
pancreatic function, and re-intervention. J Gastrointest Surg 2014;18(10):
1863e9. PMID: 24944153.
[118] Takeyama Y. Long-term prognosis of acute pancreatitis in Japan. Clin Gas-
troenterol Hepatol 2009;7(11 Suppl.):S15e7. PMID: 19896091.[119] Talamini G, Bassi C, Falconi M, Sartori N, Vaona B, Bovo P, et al. Smoking
cessation at the clinical onset of chronic pancreatitis and risk of pancreatic
calciﬁcations. Pancreas 2007;35(4):320e6. PMID: 18090237.
[120] Yadav D, O'Connell M, Papachristou GI. Natural history following the ﬁrst
attack of acute pancreatitis. Am J Gastroenterol 2012;107(7):1096e103.
PMID: 22613906.
[121] Nordback I, Pelli H, Lappalainen-Lehto R, Jarvinen S, Raty S, Sand J. The
recurrence of acute alcohol-associated pancreatitis can be reduced: a ran-
domized controlled trial. Gastroenterology 2009;136(3):848e55. PMID:
19162029.
[122] Pfutzer RH, Schneider A. Treatment of alcoholic pancreatitis. Dig Dis
2005;23(3e4):241e6. PMID: 16508288.
[123] Yadav D, Whitcomb DC. The role of alcohol and smoking in pancreatitis. Nat
Rev Gastroenterol Hepatol 2010;7(3):131e45. PMID: 20125091.
[124] Tandan M, Reddy DN, Santosh D, Vinod K, Ramchandani M, Rajesh G, et al.
Extracorporeal shock wave lithotripsy and endotherapy for pancreatic
calculi e a large single center experience. Indian J Gastroenterol 2010;29(4):
143e8. PMID: 20717860.
[125] Dumonceau JM, Costamagna G, Tringali A, Vahedi K, Delhaye M, Hittelet A,
et al. Treatment for painful calciﬁed chronic pancreatitis: extracorporeal
shock wave lithotripsy versus endoscopic treatment: a randomised
controlled trial. Gut 2007;56(4):545e52. PMID: 17047101.
[126] Cremer M, Deviere J, Delhaye M, Baize M, Vandermeeren A. Stenting in se-
vere chronic pancreatitis: results of medium-term follow-up in seventy-six
patients. Endoscopy 1991;23(3):171e6. PMID: 1860448.
[127] Vitale GC, Cothron K, Vitale EA, Rangnekar N, Zavaleta CM, Larson GM, et al.
Role of pancreatic duct stenting in the treatment of chronic pancreatitis. Surg
Endosc 2004;18(10):1431e4. PMID: 15791364.
[128] Eleftherladis N, Dinu F, Delhaye M, Le Moine O, Baize M, Vandermeeren A,
et al. Long-term outcome after pancreatic stenting in severe chronic
pancreatitis. Endoscopy 2005;37(3):223e30. PMID: 18556820.
[129] Binmoeller KF, Jue P, Seifert H, Nam WC, Izbicki J, Soehendra N. Endo-
scopic pancreatic stent drainage in chronic pancreatitis and a dominant
stricture: long-term results. Endoscopy 1995;27(9):638e44. PMID:
8903975.
[130] Costamagna G, Bulajic M, Tringali A, Pandolﬁ M, Gabbrielli A, Spada C, et al.
Multiple stenting of refractory pancreatic duct strictures in severe chronic
pancreatitis: long-term results. Endoscopy 2006;38(3):254e9. PMID:
16528652.
[131] Cahen DL, Gouma DJ, Laramee P, Nio Y, Rauws EA, Boermeester MA, et al.
Long-term outcomes of endoscopic vs surgical drainage of the pancreatic
duct in patients with chronic pancreatitis. Gastroenterology 2011;141(5):
1690e5. PMID: 21843494.
[132] Cahen DL, Gouma DJ, Nio Y, Rauws EA, Boermeester MA, Busch OR, et al.
Endoscopic versus surgical drainage of the pancreatic duct in chronic
pancreatitis. N Engl J Med 2007;356(7):676e84. PMID: 17301298.
[133] Elta GH. Is there a role for the endoscopic treatment of pain from chronic
pancreatitis? N Engl J Med 2007;356(7):727e9. PMID: 17301304.
[134] Varadarajulu S, Christein JD, Tamhane A, Drelichman ER, Wilcox CM. Pro-
spective randomized trial comparing EUS and EGD for transmural drainage
of pancreatic pseudocysts (with videos). Gastrointest Endosc 2008;68(6):
1102e11. PMID: 18640677.
[135] Shrode CW, Macdonough P, Gaidhane M, Northup PG, Sauer B, Ku J, et al.
Multimodality endoscopic treatment of pancreatic duct disruption with
stenting and pseudocyst drainage: how efﬁcacious is it? Dig Liver Dis
2013;45(2):129e33. PMID: 23036185.
[136] Kozarek RA. Endoscopic therapy of complete and partial pancreatic duct
disruptions. Gastrointest Endosc Clin N Am 1998;8(1):39e53. PMID:
9405750.
[137] Bracher GA, Manocha AP, DeBanto JR, Gates Jr LK, Slivka A, Whitcomb DC,
et al. Endoscopic pancreatic duct stenting to treat pancreatic ascites. Gas-
trointest Endosc 1999;49(6):710e5. PMID: 10343214.
[138] Varadarajulu S, Noone TC, Tutuian R, Hawes RH, Cotton PB. Predictors of
outcome in pancreatic duct disruption managed by endoscopic trans-
papillary stent placement. Gastrointest Endosc 2005;61(4):568e75. PMID:
15812410.
[139] van Boeckel PG, Vleggaar FP, Siersema PD. Plastic or metal stents for benign
extrahepatic biliary strictures: a systematic review. BMC Gastroenterol
2009;9:96. PMID: 20017920.
[140] Waldthaler A, Schutte K, Weigt J, Kropf S, Malfertheiner P, Kahl S. Long-term
outcome of self expandable metal stents for biliary obstruction in chronic
pancreatitis. JOP 2013;14(1):57e62. PMID: 23306336.
[141] Regimbeau JM, Fuks D, Bartoli E, Fumery M, Hanes A, Yzet T, et al.
A comparative study of surgery and endoscopy for the treatment of bile duct
stricture in patients with chronic pancreatitis. Surg Endosc 2012;26(10):
2902e8. PMID: 22580872.
[142] Stilling NM, Fristrup C, Wettergren A, Ugianskis A, Nygaard J, Holte K, et al.
Long-term outcome after early repair of iatrogenic bile duct injury. A na-
tional Danish multicentre study. HPB Oxf 2015;17(5):394e400. PMID:
25582034.
[143] Kaufman M, Singh G, Das S, Concha-Parra R, Erber J, Micames C, et al. Efﬁcacy
of endoscopic ultrasound-guided celiac plexus block and celiac plexus
neurolysis for managing abdominal pain associated with chronic pancreatitis
and pancreatic cancer. J Clin Gastroenterol 2010;44(2):127e34. PMID:
19826273.
M.A. Anderson et al. / Pancreatology 16 (2016) 83e9494[144] Stevens T, Costanzo A, Lopez R, Kapural L, Parsi MA, Vargo JJ. Adding
triamcinolone to endoscopic ultrasound-guided celiac plexus blockade does
not reduce pain in patients with chronic pancreatitis. Clin Gastroenterol
Hepatol 2012;10(2):186e91. 91 e1. PMID: 21946121.
[145] Buscher HC, Schipper EE, Wilder-Smith OH, Jansen JB, van Goor H. Limited
effect of thoracoscopic splanchnicectomy in the treatment of severe chronic
pancreatitis pain: a prospective long-term analysis of 75 cases. Surgery
2008;143(6):715e22. PMID: 18549887.
[146] Ahmed Ali U, Nieuwenhuijs VB, van Eijck CH, Gooszen HG, van Dam RM,
Busch OR, et al. Clinical outcome in relation to timing of surgery in chronic
pancreatitis: a nomogram to predict pain relief. Arch Surg 2012;147(10):
925e32. PMID: 23117832.
[147] Pezzilli R. Pancreas: treating pain in chronic pancreatitis e is the dilemma
over? Nat Rev Gastroenterol Hepatol 2012;9(4):191e2. PMID: 22371215.
[148] Yin Z, Sun J, Yin D, Wang J. Surgical treatment strategies in chronic
pancreatitis: a meta-analysis. Arch Surg 2012;147(10):961e8. PMID:
23070412.
[149] Sutherland DE, Radosevich DM, Bellin MD, Hering BJ, Beilman GJ, Dunn TB,
et al. Total pancreatectomy and islet autotransplantation for chronic
pancreatitis. J Am Coll Surg 2012;214(4):409e24. discussion 24e6. PMID:
22397977.
[150] Dunderdale J, McAuliffe JC, McNeal SF, Bryant SM, Yancey BD, Flowers G,
et al. Should pancreatectomy with islet cell autotransplantation in patients
with chronic alcoholic pancreatitis be abandoned? J Am Coll Surg
2013;216(4):591e6. discussion 6e8. PMID: 23521936.
[151] Nealon WH, Thompson JC. Progressive loss of pancreatic function in chronic
pancreatitis is delayed by main pancreatic duct decompression. A longitu-
dinal prospective analysis of the modiﬁed Puestow procedure. Ann Surg
1993;217(5):458e66. discussion 66e8. PMID: 8489308.
[152] Izbicki JR, Bloechle C, Broering DC, Knoefel WT, Kuechler T, Broelsch CE.
Extended drainage versus resection in surgery for chronic pancreatitis: a
prospective randomized trial comparing the longitudinal pan-
creaticojejunostomy combined with local pancreatic head excision with the
pylorus-preserving pancreatoduodenectomy. Ann Surg 1998;228(6):771e9.
PMID: 9860476.
[153] Andersen DK, Frey CF. The evolution of the surgical treatment of chronic
pancreatitis. Ann Surg 2010;251(1):18e32. PMID: 20009754.
[156] Chinnakotla S, Bellin MD, Schwarzenberg SJ, Radosevich DM, Cook M,
Dunn TB, et al. Total pancreatectomy and islet autotransplantation in chil-
dren for chronic pancreatitis: indication, surgical techniques, postoperative
management, and long-term outcomes. Ann Surg 2014;260(1):56e64.
PMID: 24509206.
[157] Ammann RW, Buehler H, Muench R, Freiburghaus AW, Siegenthaler W.
Differences in the natural history of idiopathic (nonalcoholic) and alcoholic
chronic pancreatitis. A comparative long-term study of 287 patients.
Pancreas 1987;2(4):368e77. PMID: 3628234.Further reading
[54] Terkawi AS, Jackson WM, Hansoti S, Tabassum R, Flood P. Polymorphism in
the ADRB2 gene explains a small portion of intersubject variability in painrelative to cervical dilation in the ﬁrst stage of labor. Anesthesiology
2014;121(1):140e8. PMID: 24714117.
[59] Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, et al. Catechol-
O-methyltransferase val158met polymorphism predicts placebo effect in
irritable bowel syndrome. PLoS One 2012;7(10):e48135. PMID: 23110189.
[60] Karling P, Danielsson A, Wikgren M, Soderstrom I, Del-Favero J, Adolfsson R,
et al. The relationship between the val158met catechol-O-methyltransferase
(COMT) polymorphism and irritable bowel syndrome. PLoS One 2011;6(3):
e18035. PMID: 21437260.
[61] van Esch AA, de Vries E, Te Morsche RH, van Oijen MG, Jansen JB, Drenth JP.
Catechol-O-methyltransferase (COMT) gene variants and pain in chronic
pancreatitis. Neth J Med 2009;69(7):330e4. PMID: 21934178.
[63] Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken LJ, DiMagno EP. The
different courses of early- and late-onset idiopathic and alcoholic chronic
pancreatitis. Gastroenterology 1994;107:1481e7. PMID: 7926511.
[65] Nusrat S, Yadav D, Bielefeldt K. Pain and opioid use in chronic pancreatitis.
Pancreas 2012;41(2):264e70. PMID: 21792080.
[67] Melzack R. The McGill pain questionnaire: major properties and scoring
methods. Pain 1975;1:277e99. PMID.
[68] Melzack R. The short-form McGill pain questionnaire. Pain 1987;30:191e7.
PMID.
[69] Williamson A, Hoggart B. Pain: a review of three commonly used pain rating
scales. J Clin Nurs 2005;14(7):798e804. PMID: 16000093.
[71] Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and
validity of the visual analogue scale. Pain 1983;16(1):87e101. PMID:
6602967.
[91] Dhalla S, Kopec JA. The CAGE questionnaire for alcohol misuse: a review of
reliability and validity studies. Clin Investig Med Med Clin Exp 2007;30(1):
33e41. PMID: 17716538.
[92] Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the
current opioid misuse measure to monitor chronic pain patients on opioid
therapy. Clin J Pain 2010;26(9):770e6. PMID: 20842012.
[93] Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psy-
chiatric history and psychologic adjustment as risk factors for aberrant drug-
related behavior among patients with chronic pain. Clin J Pain 2007;23(4):
307e15. PMID: 17449991.
[94] Drossman D, Szigethy E. The narcotic bowel syndrome: a recent update. Am J
Gastroenterol 2014;2(1):22e30. PMID: 25207609.
[95] Revicki DA, Chen WH, Harnam N, Cook KF, Amtmann D, Callahan LF, et al.
Development and psychometric analysis of the PROMIS pain behavior item
bank. Pain 2009;146(1e2):158e69. PMID: 19683873.
[105] Alkaade S, Balci N, Momtahen A, Burton F. Normal pancreatic exocrine
function does not exclude MRI/MRCP chronic pancreatitis ﬁndings. J Clin
Gastroenterol 2008;42:950e5 [PMID].
[154] Koninger J, Seiler CM, Sauerland S, Wente MN, Reidel MA, Muller MW, et al.
Duodenum-preserving pancreatic head resection e a randomized controlled
trial comparing the original Beger procedure with the Berne modiﬁcation
(ISRCTN no. 50638764). Surgery 2008;143(4):490e8. PMID: 18374046.
[155] Cooper MA, Makary MA, Ng J, Cui Y, Singh VK, Matsukuma K, et al. Extent of
pancreatic ﬁbrosis as a determinant of symptom resolution after the Frey
procedure: a clinico-pathologic analysis. J Gastrointest Surg Off J Soc Surg
Aliment Tract 2013;17(4):682e7. PMID: 23345052.
